NCT03577184View on ClinicalTrials.gov

Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

July 31, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

March 31, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Metformin/Vildagliptin

Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.

Sponsors

Lead Sponsor

Clinision
All Listed Sponsors
lead

Clinision

OTHER